SCHEMBL2429977

SCHEMBL2429977

Cn1cc(C(=O)Nc2cc(F)c(CC(=O)O)cc2Cl)c2ccc(F)cc21

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ITGB1 P05556 8/20 0.50
ITGA4 P13612 8/20 0.50
POLB P06746 1/20 0.40
CDK2 P24941 1/20 0.39
IDO1 P14902 1/20 0.39
TDO2 P48775 1/20 0.39
TP53 P04637 1/20 0.39
MAPT P10636 1/20 0.39
AKR1C3 P42330 1/20 0.38
AKR1C2 P52895 1/20 0.38
S1PR1 P21453 1/20 0.37
S1PR3 Q99500 1/20 0.37
PHGDH O43175 1/20 0.37
PTGDR2 Q9Y5Y4 1/20 0.36
ABCB11 O95342 1/20 0.36
PTGS1 P23219 1/20 0.36
PTGS2 P35354 1/20 0.36
PPARG P37231 1/20 0.36
NR1I3 Q14994 1/20 0.36
EP300 Q09472 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2432672 0.92 ITGB1 (0.52) ITGB1ITGA4POLBTP53MAPT
SCHEMBL14591769 0.90 ITGB1 (0.47) ITGB1ITGA4POLBCDK2IDO1
SCHEMBL71415 0.89 ITGB1 (0.60) ITGB1ITGA4MAPTEP300CREBBP
SCHEMBL14491702 0.88 ITGB1 (0.49) ITGB1ITGA4POLBCDK2IDO1
SCHEMBL92496 0.84 MAPT (0.42) ITGB1ITGA4POLBIDO1TDO2
SCHEMBL7263485 0.84 CDK2 (0.41) ITGB1ITGA4POLBCDK2IDO1
SCHEMBL5708295 0.83 ITGB1 (0.49) ITGB1ITGA4AKR1C3AKR1C2PTGS1
SCHEMBL2432198 0.82 ITGB1 (0.48) ITGB1ITGA4POLBCDK2TP53
SCHEMBL2430170 0.81 ITGB1 (0.40) ITGB1ITGA4POLBCDK2IDO1
SCHEMBL14491723 0.80 ITGB1 (0.51) ITGB1ITGA4POLBTP53MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1346982-B1 VLA-4 INHIBITORS DAIICHI SEIYAKU CO (JP) 2011-09-14 EP disclosed
US-20070149606-A1 Process for producing phenylacetic acid derivative DAIICHI PHARMACEUTICAL CO.,LTD. (JP) 2007-06-28 US disclosed
US-20070149606-A1 Process for producing phenylacetic acid derivative DAIICHI PHARMACEUTICAL CO.,LTD. (JP) 2007-06-28 US disclosed
US-7157487-B2 Vla-4 inhibitors DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-01-02 US disclosed
US-7157487-B2 Vla-4 inhibitors DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-01-02 US disclosed
US-7157487-B2 Vla-4 inhibitors DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-01-02 US disclosed
US-20040110945-A1 Vla-4 inhibitors DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-06-10 US disclosed
EP-1346982-A1 VLA-4 INHIBITORS DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2003-09-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110945-A1 Vla-4 inhibitors VCAM1, ITGA1, ITGB4 ITGB1 5/4885ITGA4 4/4885POLB 4164/4885
US-20070149606-A1 Process for producing phenylacetic acid derivative UGT1A4, VPS4B, CYP3A4 ITGB1 1987/4885ITGA4 106/4885POLB 1933/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.